Amarin Corp. PLC ADR (AMRN) News
Filter AMRN News Items
AMRN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AMRN News Highlights
- AMRN's 30 day story count now stands at 7.
- Over the past 27 days, the trend for AMRN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about AMRN are AG, ALLK and ALTO.
Latest AMRN News From Around the Web
Below are the latest news stories about Amarin Corp Plc that investors may wish to consider to help them evaluate AMRN as an investment opportunity.
JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient LevelExtensive analysis for U.S. by MedStar Health Research Institute determined icosapent ethyl is cost-effective compared to standard of care, both during the REDUCE-IT® clinical trial period and over a lifetime projectionBRIDGEWATER, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- JAMA Network Open has published “Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment,”1 which evaluated the more than 8,000 patients recruited to participate in the RED |
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Crispr Therapeutics AG (CRSP) and Allakos (ALLK)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amarin (AMRN – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and Allakos (ALLK – Research Report). Amarin (AMRN) Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Amarin today and set a price target of $10.00. The company's shares closed last Tuesday at $3.58, close to its 52-week low of $2.79. According to TipRanks.com, Ruiz is ranked 0 out of 5 stars with an average return of -20.3% and a 21.6% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Prometheus Biosciences. |
Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022 at 8:00 a.m. ET. The conference call will follow the anticipated release of the Company's financial results earlier that day. Conference Call and Webcast Information: Access to live call: |
Amarin: Revisiting Old Battles LostI haven’t covered Amarin (AMRN) in a long, long time, ever since that stock wiped out a substantial part of my investment a couple of years ago. I will list some of my previous coverage here so new readers know I was really into this stock once upon a time.... |
Regis Management CO LLC Buys Netflix Inc, Spotify Technology SA, Amarin Corp PLC, Sells Apple ...Palo Alto, CA, based Investment company Regis Management CO LLC (Current Portfolio) buys Netflix Inc, Spotify Technology SA, Amarin Corp PLC, Airbnb Inc, Juniper Networks Inc, sells Apple Inc, AvalonBay Communities Inc, Lazydays Holdings Inc, Accolade Inc, SPDR Gold Shares ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Regis Management CO LLC. |
Gratus Capital LLC Buys Fidelity Total Bond ETF, Unity Software Inc, Elastic NV, Sells Vanguard ...Investment company Gratus Capital LLC (Current Portfolio) buys Fidelity Total Bond ETF, Unity Software Inc, Elastic NV, Artisan Partners Asset Management Inc, Uber Technologies Inc, sells Vanguard Short-Term Inflation-Protected Securities, VF Corp, AT&T Inc, Block Inc, 3M Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Gratus Capital LLC. |
Why Amarin Stock Is Tumbling This WeekAmarin (NASDAQ: AMRN), a small-cap cardiovascular care company, saw its shares dip by as much as 15% during the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The good news is that Amarin's stock didn't fall in response to a company-specific event. Underscoring this point, the bellwether SPDR S&P Biotech ETF has dropped by an unsightly 14.9% over the prior four trading sessions. |
Too Early to Tell if Pfizer Job Cuts Tied to More Virtual Meetings Will Be a TrendPfizer’s long-term virtual meetings push has not come as a shock to the corporate travel sector — experts have said it could be unique to the pharmaceutical sector, rather signaling a major shift in the way organizations conduct business. The vaccine maker said it was “evolving the way we engage with healthcare professionals in an […] |
Amarin Corporation plc (AMRN) Fell Out Of Favor With Hedge Funds?As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […] |
Hikari Power Ltd Buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Sells ...Tokyo, M0, based Investment company Hikari Power Ltd (Current Portfolio) buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Jack Henry & Associates Inc, Parker Hannifin Corp, sells Anheuser-Busch InBev SA/NV, The Kraft Heinz Co, Amarin Corp PLC, ADMA Biologics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hikari Power Ltd. |